ALDX
Aldeyra Therapeutics, Inc.
Price Chart
Latest Quote
$1.63
-0.13 (-7.39%)
Current Price
| Previous Close | $1.76 |
| Open | $1.76 |
| Day High | $1.76 |
| Day Low | $1.61 |
| Volume | 946,330 |
Stock Information
| Shares Outstanding | 60.32M |
| Total Debt | $15.51M |
| Cash Equivalents | $65.00M |
| Net Income | $-27.37M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $98.32M |
| EPS (TTM) | $-0.45 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $48.83M |
| Income | $-27.37M |
| Book/sh | $0.70 |
| Cash/sh | $1.08 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 2.67 |
| Current Ratio | 2.72 |
| Debt/Eq | 36.80 |
Returns & Margins
| ROA | -22.22% |
| ROE | -51.76% |
Ownership
| Insider Ownership | 3.18% |
| Institutional Ownership | 62.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.06 |
| P/B | 2.33 |
Analyst Data
| Recommendation | buy |
| Target Price | $7.60 |
Technical Indicators
| SMA20 | $1.68 |
| SMA50 | $1.68 |
| SMA200 | $4.15 |
| RSI | 47.79 |
| ATR | 0.1284 |
| Shares Float | 52.93M |
| Short Float | 12.98% |
| Short Ratio | 7.01 |
| Volatility | 1.19 |
| Rel Volume | 0.98 |
Performance History
| Week | -6.86% |
| Month | -6.32% |
| Quarter | -66.04% |
| 6 Months | -66.53% |
| YTD | -65.10% |
| Year | -34.01% |
| 3 Years | -82.82% |
| 5 Years | -86.98% |
| 10 Years | -70.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.63 | 969,800 |
| 2026-06-04 | $1.76 | 1,073,800 |
| 2026-06-03 | $1.86 | 2,027,700 |
| 2026-06-02 | $1.64 | 959,600 |
| 2026-06-01 | $1.66 | 786,600 |
| 2026-05-29 | $1.75 | 579,500 |
| 2026-05-28 | $1.75 | 1,221,900 |
| 2026-05-27 | $1.71 | 896,800 |
| 2026-05-26 | $1.78 | 1,975,900 |
| 2026-05-22 | $1.55 | 472,900 |
| 2026-05-21 | $1.59 | 629,100 |
| 2026-05-20 | $1.55 | 840,100 |
| 2026-05-19 | $1.54 | 710,800 |
| 2026-05-18 | $1.60 | 1,043,900 |
| 2026-05-15 | $1.68 | 1,313,800 |
| 2026-05-14 | $1.66 | 709,700 |
| 2026-05-13 | $1.70 | 1,331,300 |
| 2026-05-12 | $1.71 | 718,600 |
| 2026-05-11 | $1.76 | 713,200 |
| 2026-05-08 | $1.73 | 827,600 |
| 2026-05-07 | $1.73 | 646,000 |
| 2026-05-06 | $1.74 | 1,148,100 |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
đ° Latest News
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
MarketBeat âĸ 2026-06-05T01:02:14Z
3 Promising Penny Stocks With Market Caps Reaching $300M
Simply Wall St. âĸ 2026-06-04T18:07:47Z
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value
Simply Wall St. âĸ 2026-05-15T17:38:05Z
3 Stocks That May Be Undervalued According To Analysts In May 2026
Simply Wall St. âĸ 2026-05-15T11:37:59Z
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock
Simply Wall St. âĸ 2026-05-05T10:55:06Z
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
Simply Wall St. âĸ 2026-05-01T17:38:09Z
Discover 3 Stocks That Might Be Trading Below Estimated Value
Simply Wall St. âĸ 2026-05-01T11:38:05Z
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%
Simply Wall St. âĸ 2026-04-29T17:38:07Z
3 Stocks That May Be Trading Below Their Estimated Value In April 2026
Simply Wall St. âĸ 2026-04-29T11:38:21Z
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
Simply Wall St. âĸ 2026-04-27T17:38:38Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,905,310 | $1,926,241 | $2,071,435 | $1,694,098 |
| Total Expenses | $35,265,206 | $60,117,032 | $42,794,083 | $62,679,987 |
| Net Non Operating Interest Income Expense | $1,418,545 | $4,265,588 | $5,251,573 | $655,351 |
| Interest Expense Non Operating | $1,905,310 | $1,926,241 | $2,071,435 | $1,694,098 |
| Operating Expense | $35,265,206 | $60,117,032 | $42,794,083 | $62,679,987 |
| General And Administrative Expense | $9,602,351 | $11,892,239 | $13,335,364 | $15,373,921 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net Interest Income | $1,418,545 | $4,265,588 | $5,251,573 | $655,351 |
| Interest Income | $3,323,855 | $6,191,829 | $7,323,008 | $2,349,449 |
| Normalized Income | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net Income From Continuing And Discontinued Operation | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Total Operating Income As Reported | $-35,265,206 | $-60,117,032 | $-42,794,083 | $-62,679,987 |
| Net Income Common Stockholders | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net Income | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net Income Including Noncontrolling Interests | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net Income Continuous Operations | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Pretax Income | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Interest Income Non Operating | $3,323,855 | $6,191,829 | $7,323,008 | $2,349,449 |
| Operating Income | $-35,265,206 | $-60,117,032 | $-42,794,083 | $-62,679,987 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.56 | $-0.94 | $-0.64 | $-1.06 |
| Basic EPS | $-0.56 | $-0.94 | $-0.64 | $-1.06 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-31,689,358 | $-53,675,580 | $-35,208,295 | $-60,071,831 |
| Reconciled Depreciation | $251,993 | $249,623 | $262,780 | $258,707 |
| EBITDA (Bullshit earnings) | $-31,689,358 | $-53,675,580 | $-35,208,295 | $-60,071,831 |
| EBIT | $-31,941,351 | $-53,925,203 | $-35,471,075 | $-60,330,538 |
| Diluted Average Shares | $60,056,557 | $59,484,794 | $58,943,205 | $58,405,897 |
| Basic Average Shares | $60,056,557 | $59,484,794 | $58,943,205 | $58,405,897 |
| Diluted NI Availto Com Stockholders | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Research And Development | $25,662,855 | $48,224,793 | $29,458,719 | $47,306,066 |
| Selling General And Administration | $9,602,351 | $11,892,239 | $13,335,364 | $15,373,921 |
| Other Gand A | $9,602,351 | $11,892,239 | $13,335,364 | $15,373,921 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
| Tax Provision | - | - | - | - |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $44,250,390 | $71,004,871 | $119,795,030 | $151,008,029 |
| Total Assets | $72,059,317 | $104,606,694 | $148,326,911 | $181,291,657 |
| Total Non Current Assets | $275,861 | $534,216 | $516,578 | $268,544 |
| Non Current Deferred Assets | $0 | $267,261 | $0 | - |
| Current Assets | $71,783,456 | $104,072,478 | $147,810,333 | $181,023,113 |
| Other Current Assets | $291,922 | $301,152 | $183,146 | $442,721 |
| Current Deferred Assets | $1,043,086 | $2,211,963 | $4,463,783 | $2,605,252 |
| Prepaid Assets | $407,194 | $408,091 | $340,388 | $432,230 |
| Cash Cash Equivalents And Short Term Investments | $70,041,254 | $101,151,272 | $142,823,016 | $174,300,884 |
| Cash And Cash Equivalents | $70,041,254 | $54,527,092 | $142,823,016 | $144,419,364 |
| Cash Equivalents | $40,474,518 | $30,793,079 | $14,312,565 | $9,268,283 |
| Cash Financial | $29,566,736 | $23,734,013 | $128,510,451 | $135,151,081 |
| Receivables | - | - | $0 | $3,242,026 |
| Other Receivables | - | - | - | $3,242,026 |
| Debt | ||||
| Total Debt | $15,530,169 | $15,303,003 | $15,657,360 | $16,084,118 |
| Current Debt And Capital Lease Obligation | $15,530,169 | $303,003 | $15,385,729 | $1,161,028 |
| Current Debt | $15,249,632 | $31,372 | $15,146,546 | $911,763 |
| Other Current Borrowings | $15,249,632 | $31,372 | $15,146,546 | $911,763 |
| Long Term Debt And Capital Lease Obligation | - | $15,000,000 | $271,631 | $14,923,090 |
| Long Term Debt | - | $15,000,000 | - | $14,923,090 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $27,808,927 | $33,601,823 | $28,531,881 | $30,283,628 |
| Total Non Current Liabilities Net Minority Interest | $0 | $15,000,000 | $6,271,631 | $14,923,090 |
| Current Liabilities | $27,808,927 | $18,601,823 | $22,260,250 | $15,360,538 |
| Current Deferred Liabilities | $6,000,000 | $6,000,000 | $0 | - |
| Payables And Accrued Expenses | $2,005,759 | $7,965,604 | $3,786,584 | $10,377,606 |
| Payables | $158,461 | $180,453 | $1,338,057 | $133,625 |
| Accounts Payable | $158,461 | $180,453 | $1,338,057 | $133,625 |
| Non Current Deferred Liabilities | - | $0 | $6,000,000 | $0 |
| Equity | ||||
| Common Stock Equity | $44,250,390 | $71,004,871 | $119,795,030 | $151,008,029 |
| Total Equity Gross Minority Interest | $44,250,390 | $71,004,871 | $119,795,030 | $151,008,029 |
| Stockholders Equity | $44,250,390 | $71,004,871 | $119,795,030 | $151,008,029 |
| Gains Losses Not Affecting Retained Earnings | $0 | $37,442 | $0 | $-103,938 |
| Retained Earnings | $-483,957,253 | $-450,110,592 | $-394,259,148 | $-356,716,638 |
| Other Equity Adjustments | - | $37,442 | - | $-103,938 |
| Other | ||||
| Ordinary Shares Number | $60,162,773 | $59,648,278 | $59,195,951 | $58,560,078 |
| Share Issued | $60,162,773 | $59,648,278 | $59,195,951 | $58,560,078 |
| Tangible Book Value | $44,250,390 | $71,004,871 | $119,795,030 | $151,008,029 |
| Invested Capital | $59,500,022 | $86,036,243 | $134,941,576 | $166,842,882 |
| Working Capital | $43,974,529 | $85,470,655 | $125,550,083 | $165,662,575 |
| Capital Lease Obligations | $280,537 | $271,631 | $510,814 | $249,265 |
| Total Capitalization | $44,250,390 | $86,004,871 | $119,795,030 | $165,931,119 |
| Additional Paid In Capital | $528,147,480 | $521,018,373 | $513,994,982 | $507,770,045 |
| Capital Stock | $60,163 | $59,648 | $59,196 | $58,560 |
| Common Stock | $60,163 | $59,648 | $59,196 | $58,560 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | $6,000,000 | $6,000,000 | $0 | - |
| Current Capital Lease Obligation | $280,537 | $271,631 | $239,183 | $249,265 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,272,999 | $4,333,216 | $3,087,937 | $3,821,904 |
| Current Accrued Expenses | $1,847,298 | $7,785,151 | $2,448,527 | $10,243,981 |
| Net PPE | $275,861 | $266,955 | $516,578 | $268,544 |
| Gross PPE | $275,861 | $266,955 | $516,578 | $268,544 |
| Other Properties | $275,861 | $266,955 | $516,578 | $268,544 |
| Other Short Term Investments | $0 | $46,624,180 | $0 | $29,881,520 |
| Non Current Deferred Revenue | - | $0 | $6,000,000 | $0 |
| Long Term Capital Lease Obligation | - | $0 | $271,631 | $0 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-33,345,682 | $-43,208,747 | $-30,326,128 | $-56,653,504 |
| Operating Activities | ||||
| Operating Cash Flow | $-33,345,682 | $-43,208,747 | $-30,326,128 | $-56,637,187 |
| Cash Flow From Continuing Operating Activities | $-33,345,682 | $-43,208,747 | $-30,326,128 | $-56,637,187 |
| Investing Activities | ||||
| Investing Cash Flow | $47,736,288 | $-44,915,755 | $30,000,000 | $-29,954,530 |
| Cash Flow From Continuing Investing Activities | $47,736,288 | $-44,915,755 | $30,000,000 | $-29,954,530 |
| Capital Expenditure | - | - | - | $-16,317 |
| Financing Activities | ||||
| Financing Cash Flow | $1,123,556 | $-171,422 | $-1,270,220 | $1,220,092 |
| Cash Flow From Continuing Financing Activities | $1,123,556 | $-171,422 | $-1,270,220 | $1,220,092 |
| Net Other Financing Charges | - | $-267,261 | $-532,951 | - |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-292,500 | $-1,042,500 | $0 |
| Interest Paid Supplemental Data | $1,688,125 | $1,753,792 | $1,702,188 | $1,338,542 |
| End Cash Position | $70,041,254 | $54,527,092 | $142,823,016 | $144,419,364 |
| Beginning Cash Position | $54,527,092 | $142,823,016 | $144,419,364 | $229,790,989 |
| Changes In Cash | $15,514,162 | $-88,295,924 | $-1,596,348 | $-85,371,625 |
| Proceeds From Stock Option Exercised | $1,123,556 | $388,339 | $305,231 | $1,220,092 |
| Net Issuance Payments Of Debt | $0 | $-292,500 | $-1,042,500 | $0 |
| Net Long Term Debt Issuance | $0 | $-292,500 | $-1,042,500 | $0 |
| Long Term Debt Payments | $0 | $-292,500 | $-1,042,500 | $0 |
| Net Investment Purchase And Sale | $47,736,288 | $-44,915,755 | $30,000,000 | $-29,938,213 |
| Sale Of Investment | $88,000,000 | $52,000,000 | $30,000,000 | $63,000,000 |
| Purchase Of Investment | $-40,263,712 | $-96,915,755 | $0 | $-92,938,213 |
| Change In Working Capital | $-5,178,398 | $5,913,232 | $861,180 | $-3,444,139 |
| Change In Payables And Accrued Expense | $-6,357,402 | $3,847,121 | $-6,873,732 | $316,309 |
| Change In Accrued Expense | $-6,335,410 | $5,004,725 | $-8,078,164 | $1,202,386 |
| Change In Payable | $-21,992 | $-1,157,604 | $1,204,432 | $-886,077 |
| Change In Account Payable | $-21,992 | $-1,157,604 | $1,204,432 | $-886,077 |
| Change In Prepaid Assets | $1,179,004 | $2,066,111 | $1,734,912 | $-3,760,448 |
| Other Non Cash Items | $218,260 | $177,326 | $354,193 | $331,150 |
| Stock Based Compensation | $6,091,413 | $7,973,499 | $5,752,771 | $8,288,976 |
| Asset Impairment Charge | $267,261 | $0 | - | - |
| Amortization Of Securities | $-1,149,550 | $-1,670,983 | $-14,542 | $-47,245 |
| Depreciation Amortization Depletion | $251,993 | $249,623 | $262,780 | $258,707 |
| Depreciation And Amortization | $251,993 | $249,623 | $262,780 | $258,707 |
| Net Income From Continuing Operations | $-33,846,661 | $-55,851,444 | $-37,542,510 | $-62,024,636 |
| Net PPE Purchase And Sale | - | - | $0 | $-16,317 |
| Purchase Of PPE | - | - | $0 | $-16,317 |
| Change In Other Working Capital | - | - | $6,000,000 | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-05-30